{"id": "article-149474_0", "title": "Hypereosinophilic Syndrome -- Introduction", "content": "Hypereosinophilic syndrome (HES) encompasses a rare and complex group of heterogeneous disorders characterized by persistent and substantial elevations in eosinophil levels and mediators leading to tissue infiltration and damage. [1] Eosinophilopoiesis plays a vital role in the pro-inflammatory processes of multiple diseases. The HES criteria are as follows: Hypereosinophilia is characterized by >1.5 x 10 9 eosinophils on CBC on 2 examinations >1 month apart. The percentage of eosinophils in the bone marrow (BM) section must exceed 20% of all nucleated cells The pathologist's\u00a0assessment that the tissue infiltration by eosinophils is extensive and/or marked deposition of eosinophil granule proteins is found. Evidence of organ or tissue damage attributable to tissue hypereosinophilia (HE). Exclusion of other disorders or conditions as major reasons for organ damage.", "contents": "Hypereosinophilic Syndrome -- Introduction. Hypereosinophilic syndrome (HES) encompasses a rare and complex group of heterogeneous disorders characterized by persistent and substantial elevations in eosinophil levels and mediators leading to tissue infiltration and damage. [1] Eosinophilopoiesis plays a vital role in the pro-inflammatory processes of multiple diseases. The HES criteria are as follows: Hypereosinophilia is characterized by >1.5 x 10 9 eosinophils on CBC on 2 examinations >1 month apart. The percentage of eosinophils in the bone marrow (BM) section must exceed 20% of all nucleated cells The pathologist's\u00a0assessment that the tissue infiltration by eosinophils is extensive and/or marked deposition of eosinophil granule proteins is found. Evidence of organ or tissue damage attributable to tissue hypereosinophilia (HE). Exclusion of other disorders or conditions as major reasons for organ damage."}
{"id": "article-149474_1", "title": "Hypereosinophilic Syndrome -- Etiology", "content": "Based on the initial patient evaluation, HES can be classified into 5 clinically relevant variants: [2]", "contents": "Hypereosinophilic Syndrome -- Etiology. Based on the initial patient evaluation, HES can be classified into 5 clinically relevant variants: [2]"}
{"id": "article-149474_2", "title": "Hypereosinophilic Syndrome -- Etiology -- Primary/Neoplastic (HESN)", "content": "Myeloid variants (M-HES): Classified into various subtypes, including platelet-derived growth factor receptor alpha FIP1L1-PDGFRA fusion gene (F/P pos variant), which occurs secondary to an interstitial chromosomal deletion on 4q12. Platelet-derived growth factor receptor beta (PDGFRB) such as t(5;12)(q31-35;p13), janus kinase 2 (JAK 2) point mutation and translocation formed by t(8;9)(p22;p24), fibroblast growth factor receptor 1 ( FGFR1 ) rearrangements such as (8p11-12), chronic eosinophilic leukemia (CEL), and HES with myeloid features without known mutation. [1] [3] [4] T-cell lymphocytic variants (L-HES): Caused by aberrant IL-5-producing T-cells, such as CD3-CD4+ T cell-associated disease.", "contents": "Hypereosinophilic Syndrome -- Etiology -- Primary/Neoplastic (HESN). Myeloid variants (M-HES): Classified into various subtypes, including platelet-derived growth factor receptor alpha FIP1L1-PDGFRA fusion gene (F/P pos variant), which occurs secondary to an interstitial chromosomal deletion on 4q12. Platelet-derived growth factor receptor beta (PDGFRB) such as t(5;12)(q31-35;p13), janus kinase 2 (JAK 2) point mutation and translocation formed by t(8;9)(p22;p24), fibroblast growth factor receptor 1 ( FGFR1 ) rearrangements such as (8p11-12), chronic eosinophilic leukemia (CEL), and HES with myeloid features without known mutation. [1] [3] [4] T-cell lymphocytic variants (L-HES): Caused by aberrant IL-5-producing T-cells, such as CD3-CD4+ T cell-associated disease."}
{"id": "article-149474_3", "title": "Hypereosinophilic Syndrome -- Etiology -- Secondary/Reactive (HESR)", "content": "Specific/defined hypereosinophilic syndromes secondary to an underlying condition such as an infectious or inflammatory process. Examples include: helminth infections, episodic angioedema, and eosinophilic granulomatosis with polyangiitis (EGPA).", "contents": "Hypereosinophilic Syndrome -- Etiology -- Secondary/Reactive (HESR). Specific/defined hypereosinophilic syndromes secondary to an underlying condition such as an infectious or inflammatory process. Examples include: helminth infections, episodic angioedema, and eosinophilic granulomatosis with polyangiitis (EGPA)."}
{"id": "article-149474_4", "title": "Hypereosinophilic Syndrome -- Etiology -- Familial HES (HESFA)", "content": "Namely when there is a family history of documented persistent hypereosinophilia of unknown cause.", "contents": "Hypereosinophilic Syndrome -- Etiology -- Familial HES (HESFA). Namely when there is a family history of documented persistent hypereosinophilia of unknown cause."}
{"id": "article-149474_5", "title": "Hypereosinophilic Syndrome -- Etiology -- Idiopathic (IHES)", "content": "Hypereosinophilia with no clear underlying cause associated with end-organ damage.", "contents": "Hypereosinophilic Syndrome -- Etiology -- Idiopathic (IHES). Hypereosinophilia with no clear underlying cause associated with end-organ damage."}
{"id": "article-149474_6", "title": "Hypereosinophilic Syndrome -- Etiology -- Organ-Restricted HES", "content": "Namely, when tissue hypereosinophilia is present, it causes end-organ damage, but HES blood criteria are unmet.", "contents": "Hypereosinophilic Syndrome -- Etiology -- Organ-Restricted HES. Namely, when tissue hypereosinophilia is present, it causes end-organ damage, but HES blood criteria are unmet."}
{"id": "article-149474_7", "title": "Hypereosinophilic Syndrome -- Epidemiology", "content": "The true incidence and prevalence of hypereosinophilic syndromes is unknown. A 2010 study utilizing the Surveillance, Epidemiology, and End Results (SEER) database showed an estimated age-adjusted incidence rate between 0.16 and 0.36 per 100,000 and prevalence (calculated as a product of incidence times duration of chronic disease) between 0.36 to 6.3 per 100,000. [5]", "contents": "Hypereosinophilic Syndrome -- Epidemiology. The true incidence and prevalence of hypereosinophilic syndromes is unknown. A 2010 study utilizing the Surveillance, Epidemiology, and End Results (SEER) database showed an estimated age-adjusted incidence rate between 0.16 and 0.36 per 100,000 and prevalence (calculated as a product of incidence times duration of chronic disease) between 0.36 to 6.3 per 100,000. [5]"}
{"id": "article-149474_8", "title": "Hypereosinophilic Syndrome -- Epidemiology", "content": "While HES occurs more commonly between the ages of 20 to 50, some pediatric cases\u00a0are reported. [6] [7] Studies suggest that the frequencies of HES variants\u00a0are similar between children and adults. Children with primary immunodeficiency more commonly present with secondary HES than adults. In addition, children were noted to have higher median peak absolute eosinophil count, more gastrointestinal complaints, and less pulmonary involvement. [8]", "contents": "Hypereosinophilic Syndrome -- Epidemiology. While HES occurs more commonly between the ages of 20 to 50, some pediatric cases\u00a0are reported. [6] [7] Studies suggest that the frequencies of HES variants\u00a0are similar between children and adults. Children with primary immunodeficiency more commonly present with secondary HES than adults. In addition, children were noted to have higher median peak absolute eosinophil count, more gastrointestinal complaints, and less pulmonary involvement. [8]"}
{"id": "article-149474_9", "title": "Hypereosinophilic Syndrome -- Pathophysiology", "content": "As versatile leukocytes, eosinophils exhibit potent pro-inflammatory, prothrombotic, and pro-fibrotic properties. The multifunctional\u00a0properties\u00a0can cause organs to become infiltrated, resulting in end-organ dysfunction. [9] [10] Tissue infiltration by eosinophils, especially in conditions like eosinophilic pneumonia, is pathological.", "contents": "Hypereosinophilic Syndrome -- Pathophysiology. As versatile leukocytes, eosinophils exhibit potent pro-inflammatory, prothrombotic, and pro-fibrotic properties. The multifunctional\u00a0properties\u00a0can cause organs to become infiltrated, resulting in end-organ dysfunction. [9] [10] Tissue infiltration by eosinophils, especially in conditions like eosinophilic pneumonia, is pathological."}
{"id": "article-149474_10", "title": "Hypereosinophilic Syndrome -- Pathophysiology", "content": "Fibroblast activation, proliferation, and secretion of transforming growth factor-beta (TGF-B) and interleukin-1B (IL-1B) play a crucial role. The toxic granule proteins stored within eosinophils, including eosinophil cationic protein (ECP), promote the release of TGF-B, initiating eosinophil-mediated tissue fibrosis. Numerous studies have substantiated the involvement of eosinophil infiltration in inflammatory fibrotic lesions. [11] [12] [13]", "contents": "Hypereosinophilic Syndrome -- Pathophysiology. Fibroblast activation, proliferation, and secretion of transforming growth factor-beta (TGF-B) and interleukin-1B (IL-1B) play a crucial role. The toxic granule proteins stored within eosinophils, including eosinophil cationic protein (ECP), promote the release of TGF-B, initiating eosinophil-mediated tissue fibrosis. Numerous studies have substantiated the involvement of eosinophil infiltration in inflammatory fibrotic lesions. [11] [12] [13]"}
{"id": "article-149474_11", "title": "Hypereosinophilic Syndrome -- Pathophysiology", "content": "Allergic reactions contribute to the inflammatory process. Th2 cells, fostering an interleukin-5 (IL-5) rich environment, facilitate eosinophil migration, infiltration, and heightened inflammation in the affected organ. [14]", "contents": "Hypereosinophilic Syndrome -- Pathophysiology. Allergic reactions contribute to the inflammatory process. Th2 cells, fostering an interleukin-5 (IL-5) rich environment, facilitate eosinophil migration, infiltration, and heightened inflammation in the affected organ. [14]"}
{"id": "article-149474_12", "title": "Hypereosinophilic Syndrome -- Pathophysiology", "content": "Lastly, eosinophil-mediated disorders are associated with an elevated thrombotic risk, potentially attributed to eosinophil tissue factor (TF) expression.\u00a0The prothrombotic\u00a0quality\u00a0induces a hypercoagulable state influenced by the platelet-activating effects of eosinophilic granules. [15] [16]", "contents": "Hypereosinophilic Syndrome -- Pathophysiology. Lastly, eosinophil-mediated disorders are associated with an elevated thrombotic risk, potentially attributed to eosinophil tissue factor (TF) expression.\u00a0The prothrombotic\u00a0quality\u00a0induces a hypercoagulable state influenced by the platelet-activating effects of eosinophilic granules. [15] [16]"}
{"id": "article-149474_13", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "According to a retrospective analysis of patients between 2001 to 2006, approximately 37% experienced dermatologic signs and symptoms. Around 25%\u00a0of these were pulmonary, followed by 14% gastrointestinal, 5% cardiac, and 4% neurologic. [17]", "contents": "Hypereosinophilic Syndrome -- History and Physical. According to a retrospective analysis of patients between 2001 to 2006, approximately 37% experienced dermatologic signs and symptoms. Around 25%\u00a0of these were pulmonary, followed by 14% gastrointestinal, 5% cardiac, and 4% neurologic. [17]"}
{"id": "article-149474_14", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "Dermatologic manifestations associated with HES encompass a spectrum of conditions, including eczema, erythroderma, skin lichenification, dermographism, urticaria, and angioedema. Notably, prominent cutaneous symptoms may indicate L-HES, warranting\u00a0suspicion\u00a0of potential cutaneous T-cell lymphoma. Initial signs of HES may manifest as skin lesions on the trunk and extremities, presenting as pruritic erythematous macules, papules, plaques, wheals, and nodules. [18] While infrequent, more severe dermatologic manifestations of HES, particularly the FIP1L1-PDGFRA variant, may extend to mucosal ulcerations within the gastrointestinal tract, ranging from the oral mucosa to the rectum. Additionally, signs indicative of lymphomatoid papulosis may be observed in these cases. [19]", "contents": "Hypereosinophilic Syndrome -- History and Physical. Dermatologic manifestations associated with HES encompass a spectrum of conditions, including eczema, erythroderma, skin lichenification, dermographism, urticaria, and angioedema. Notably, prominent cutaneous symptoms may indicate L-HES, warranting\u00a0suspicion\u00a0of potential cutaneous T-cell lymphoma. Initial signs of HES may manifest as skin lesions on the trunk and extremities, presenting as pruritic erythematous macules, papules, plaques, wheals, and nodules. [18] While infrequent, more severe dermatologic manifestations of HES, particularly the FIP1L1-PDGFRA variant, may extend to mucosal ulcerations within the gastrointestinal tract, ranging from the oral mucosa to the rectum. Additionally, signs indicative of lymphomatoid papulosis may be observed in these cases. [19]"}
{"id": "article-149474_15", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "Pulmonary manifestations of HES include asthma-like symptoms, including dyspnea, cough, and wheezing. Abnormal findings such as\u00a0patchy ground-glass infiltrates and consolidation within the pulmonary parenchyma\u00a0are observed on chest radiography or computed tomography (CT). Although less frequently observed, pulmonary nodules may be present. Other associated features include pleural effusion, intrathoracic lymphadenopathy, and occurrences of pulmonary emboli. [20] Histologic examination\u00a0by lung biopsy typically reveals eosinophilic infiltrates.", "contents": "Hypereosinophilic Syndrome -- History and Physical. Pulmonary manifestations of HES include asthma-like symptoms, including dyspnea, cough, and wheezing. Abnormal findings such as\u00a0patchy ground-glass infiltrates and consolidation within the pulmonary parenchyma\u00a0are observed on chest radiography or computed tomography (CT). Although less frequently observed, pulmonary nodules may be present. Other associated features include pleural effusion, intrathoracic lymphadenopathy, and occurrences of pulmonary emboli. [20] Histologic examination\u00a0by lung biopsy typically reveals eosinophilic infiltrates."}
{"id": "article-149474_16", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "Gastrointestinal involvement includes colitis or enteritis, eosinophilic gastritis, chronic active hepatitis, focal hepatic lesions, eosinophilic cholangitis, and Budd-Chiari syndrome. These may present as dysphagia, weight loss, abdominal pain, nausea, vomiting, and diarrhea. [21]", "contents": "Hypereosinophilic Syndrome -- History and Physical. Gastrointestinal involvement includes colitis or enteritis, eosinophilic gastritis, chronic active hepatitis, focal hepatic lesions, eosinophilic cholangitis, and Budd-Chiari syndrome. These may present as dysphagia, weight loss, abdominal pain, nausea, vomiting, and diarrhea. [21]"}
{"id": "article-149474_17", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "Cardiac manifestations exhibit a higher incidence in FIP1L1-PDGFRA-associated HES. This phenomenon arises from the infiltration of eosinophils into the myocardium, leading to myocardial necrosis due to the release of toxic cationic proteins and enhanced leukocyte recruitment or activation. [6] This process can progress to fatal endomyocardial fibrosis. [22] Typically, the clinical presentation includes signs of heart failure, such as dyspnea, chest pain, cough, and palpitations. However, it may also manifest with signs and symptoms of pericarditis, myocardial ischemia, and intracardiac thrombus. [23] [24]", "contents": "Hypereosinophilic Syndrome -- History and Physical. Cardiac manifestations exhibit a higher incidence in FIP1L1-PDGFRA-associated HES. This phenomenon arises from the infiltration of eosinophils into the myocardium, leading to myocardial necrosis due to the release of toxic cationic proteins and enhanced leukocyte recruitment or activation. [6] This process can progress to fatal endomyocardial fibrosis. [22] Typically, the clinical presentation includes signs of heart failure, such as dyspnea, chest pain, cough, and palpitations. However, it may also manifest with signs and symptoms of pericarditis, myocardial ischemia, and intracardiac thrombus. [23] [24]"}
{"id": "article-149474_18", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "The progression of eosinophil-mediated heart damage comprises\u00a03 main stages, which do not always occur in sequence. The acute necrotic stage, often clinically silent with a normal physical exam, involves myocardial infiltration with eosinophils and lymphocytes, followed by eosinophil degranulation, myocardial necrosis, and the formation of sterile microabscesses.", "contents": "Hypereosinophilic Syndrome -- History and Physical. The progression of eosinophil-mediated heart damage comprises\u00a03 main stages, which do not always occur in sequence. The acute necrotic stage, often clinically silent with a normal physical exam, involves myocardial infiltration with eosinophils and lymphocytes, followed by eosinophil degranulation, myocardial necrosis, and the formation of sterile microabscesses."}
{"id": "article-149474_19", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "In the intermediate phase, thrombus formation occurs due to eosinophil peroxidase generating an acidic compound called hypothiocyanous acid, which diffuses into the endothelial cells, inducing tissue factor expression. Tissue factor\u00a0promotes thrombogenesis and attaches to the damaged endocardium, leading to serious complications, such as embolic stroke, limb ischemia, and other embolic events. [25] [26] Patients should be\u00a0anticoagulated promptly\u00a0when the underlying cause is investigated.", "contents": "Hypereosinophilic Syndrome -- History and Physical. In the intermediate phase, thrombus formation occurs due to eosinophil peroxidase generating an acidic compound called hypothiocyanous acid, which diffuses into the endothelial cells, inducing tissue factor expression. Tissue factor\u00a0promotes thrombogenesis and attaches to the damaged endocardium, leading to serious complications, such as embolic stroke, limb ischemia, and other embolic events. [25] [26] Patients should be\u00a0anticoagulated promptly\u00a0when the underlying cause is investigated."}
{"id": "article-149474_20", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "The fibrotic stage, known as eosinophilic myocardial fibrosis (EMF), occurs secondary to myocardial scarring. It may involve ventricles and the subvalvular apparatus or mitral and tricuspid valves. EMF is responsible for restrictive cardiomyopathy of\u00a0poor prognosis as well as fatal ventricular arrhythmias secondary to alterations of the cardiac conduction system. [27]", "contents": "Hypereosinophilic Syndrome -- History and Physical. The fibrotic stage, known as eosinophilic myocardial fibrosis (EMF), occurs secondary to myocardial scarring. It may involve ventricles and the subvalvular apparatus or mitral and tricuspid valves. EMF is responsible for restrictive cardiomyopathy of\u00a0poor prognosis as well as fatal ventricular arrhythmias secondary to alterations of the cardiac conduction system. [27]"}
{"id": "article-149474_21", "title": "Hypereosinophilic Syndrome -- History and Physical", "content": "Neurologic manifestations of HES may present as central or peripheral symptoms. Central symptoms include encephalopathy and organic psychosyndrome. Peripheral symptoms account for over 50% of neurologic symptoms of HES and present as peripheral neuropathy, mononeuropathy multiplex, autonomic neuropathy, and polymyositis. [28] Other signs may occur due to thromboembolic disease, such as intracardiac thrombus, encephalopathy likely secondary to microvascular occlusion, peripheral neuropathy, and sinus thrombosis. [28]", "contents": "Hypereosinophilic Syndrome -- History and Physical. Neurologic manifestations of HES may present as central or peripheral symptoms. Central symptoms include encephalopathy and organic psychosyndrome. Peripheral symptoms account for over 50% of neurologic symptoms of HES and present as peripheral neuropathy, mononeuropathy multiplex, autonomic neuropathy, and polymyositis. [28] Other signs may occur due to thromboembolic disease, such as intracardiac thrombus, encephalopathy likely secondary to microvascular occlusion, peripheral neuropathy, and sinus thrombosis. [28]"}
{"id": "article-149474_22", "title": "Hypereosinophilic Syndrome -- Evaluation", "content": "Evaluation of patients presenting with eosinophilia should start with a focused history that identifies known and treatable causes. This includes screening for parasitic infections through stool testing for ova and parasites and investigating potential adverse drug reactions, including those associated with natural supplements. Subsequent steps should\u00a0detect any evidence of end-organ involvement. It is crucial to remember that end-organ damage may manifest insidiously and does not always correlate with the degree of hypereosinophilia. [29]", "contents": "Hypereosinophilic Syndrome -- Evaluation. Evaluation of patients presenting with eosinophilia should start with a focused history that identifies known and treatable causes. This includes screening for parasitic infections through stool testing for ova and parasites and investigating potential adverse drug reactions, including those associated with natural supplements. Subsequent steps should\u00a0detect any evidence of end-organ involvement. It is crucial to remember that end-organ damage may manifest insidiously and does not always correlate with the degree of hypereosinophilia. [29]"}
{"id": "article-149474_23", "title": "Hypereosinophilic Syndrome -- Evaluation", "content": "In patients meeting the diagnostic criteria for HES without an identified underlying cause of eosinophilia, further investigation is warranted to delineate HES variants. [3] Initial laboratory studies should include\u00a0CBC with differential, comprehensive blood chemistries, liver enzymes, renal function tests, creatine kinase, and troponin levels. Additional diagnostic and imaging studies to initiate include electrocardiogram, echocardiogram, pulmonary function tests, chest radiography,\u00a0CT of the chest and abdomen, and tissue biopsies if indicated. Hematologic evaluation\u00a0aims at investigating the underlying cause of HES, including:", "contents": "Hypereosinophilic Syndrome -- Evaluation. In patients meeting the diagnostic criteria for HES without an identified underlying cause of eosinophilia, further investigation is warranted to delineate HES variants. [3] Initial laboratory studies should include\u00a0CBC with differential, comprehensive blood chemistries, liver enzymes, renal function tests, creatine kinase, and troponin levels. Additional diagnostic and imaging studies to initiate include electrocardiogram, echocardiogram, pulmonary function tests, chest radiography,\u00a0CT of the chest and abdomen, and tissue biopsies if indicated. Hematologic evaluation\u00a0aims at investigating the underlying cause of HES, including:"}
{"id": "article-149474_24", "title": "Hypereosinophilic Syndrome -- Evaluation", "content": "Fluorescence in situ hybridization (FISH) to detect CHIC2 deletion or RT-PCR on peripheral blood to test for FIP1L1-PDGFRA mutation. [30] Flow-cytometry, staining, and analysis\u00a0on peripheral blood to detect specific t-lymphocyte phenotypes, such as CD3, CD4, and CD8 Bone marrow aspiration and biopsy\u00a0to reveal increased eosinophils and eosinophil precursors. Dysplasia, CD34 expression, fibrosis, mast cells, and karyotyping should be considered. [31] Molecular studies to detect the presence of fusion genes such as FGFR1 and PDGFRB, as well as other mutations, including BCR-ABL1, JAK2 V617F, KIT D816V, and clonal T cell receptor arrangements. [32] [33] When suspecting specific variants, certain testing may provide diagnostic benefits. [34]", "contents": "Hypereosinophilic Syndrome -- Evaluation. Fluorescence in situ hybridization (FISH) to detect CHIC2 deletion or RT-PCR on peripheral blood to test for FIP1L1-PDGFRA mutation. [30] Flow-cytometry, staining, and analysis\u00a0on peripheral blood to detect specific t-lymphocyte phenotypes, such as CD3, CD4, and CD8 Bone marrow aspiration and biopsy\u00a0to reveal increased eosinophils and eosinophil precursors. Dysplasia, CD34 expression, fibrosis, mast cells, and karyotyping should be considered. [31] Molecular studies to detect the presence of fusion genes such as FGFR1 and PDGFRB, as well as other mutations, including BCR-ABL1, JAK2 V617F, KIT D816V, and clonal T cell receptor arrangements. [32] [33] When suspecting specific variants, certain testing may provide diagnostic benefits. [34]"}
{"id": "article-149474_25", "title": "Hypereosinophilic Syndrome -- Evaluation", "content": "M-HES variants are notable for increased serum B12 and FIP1L1-PDGFRA fusion genes. Anemia, thrombocytopenia, elevated serum tryptase, and hepatosplenomegaly have been noted. L-HES presents dermatologic symptoms, although other organs may be involved. Molecular testing\u00a0could reveal abnormal T cell markers, including CD3-CD4+, CD3+CD4-CD8-, and CD4+CD7-, among others. Further testing includes T cell receptor and cytogenetic studies to determine the presence of T cell clonality and rare karyotypic abnormalities. Presence or exposure to Epstein-Barr virus (EBV) should be defined since chronic infection\u00a0could drive L-HES. [35] Other tests noted in L-HES cases include elevated immunoglobulins such as IgE, elevated serum thymus, activation-regulated chemokine (TARC), and IL-5.", "contents": "Hypereosinophilic Syndrome -- Evaluation. M-HES variants are notable for increased serum B12 and FIP1L1-PDGFRA fusion genes. Anemia, thrombocytopenia, elevated serum tryptase, and hepatosplenomegaly have been noted. L-HES presents dermatologic symptoms, although other organs may be involved. Molecular testing\u00a0could reveal abnormal T cell markers, including CD3-CD4+, CD3+CD4-CD8-, and CD4+CD7-, among others. Further testing includes T cell receptor and cytogenetic studies to determine the presence of T cell clonality and rare karyotypic abnormalities. Presence or exposure to Epstein-Barr virus (EBV) should be defined since chronic infection\u00a0could drive L-HES. [35] Other tests noted in L-HES cases include elevated immunoglobulins such as IgE, elevated serum thymus, activation-regulated chemokine (TARC), and IL-5."}
{"id": "article-149474_26", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Whether a patient\u00a0needs treatment for HES depends on the underlying cause and disease severity. Individuals with undetermined causes of HES should undergo a comprehensive evaluation to identify treatable factors, such as drug hypersensitivity and helminth infection, and assess for M-HES associated with the FIP1L1-PDGFRA transcription gene. Therapeutic objectives include reducing the eosinophil count, improving disease symptoms, and preventing disease progression. [36] The timing of therapy is contingent upon disease severity, including the degree of hypereosinophilia and the impact of symptoms on the patient\u2019s well-being. For pauci-symptomatic patients, regular follow-up every 3 months to evaluate for end-organ involvement\u00a0is sufficient.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Whether a patient\u00a0needs treatment for HES depends on the underlying cause and disease severity. Individuals with undetermined causes of HES should undergo a comprehensive evaluation to identify treatable factors, such as drug hypersensitivity and helminth infection, and assess for M-HES associated with the FIP1L1-PDGFRA transcription gene. Therapeutic objectives include reducing the eosinophil count, improving disease symptoms, and preventing disease progression. [36] The timing of therapy is contingent upon disease severity, including the degree of hypereosinophilia and the impact of symptoms on the patient\u2019s well-being. For pauci-symptomatic patients, regular follow-up every 3 months to evaluate for end-organ involvement\u00a0is sufficient."}
{"id": "article-149474_27", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Severe HES is defined by an absolute eosinophil count of 100 x 10 9 /L (>100,000 cells/\u00b5L) and signs of hyperleukocytosis involving the nervous and pulmonary systems. In cases of severe HES, treatment involves high-dose intravenous prednisone 1 mg/kg/ day or 1 g/day of methylprednisolone. Patients should be tested for Strongyloides serology before initiating treatment if uncertainty exists regarding prior exposure.\u00a0Prophylaxis with\u00a0ivermectin at 200 mcg/kg/daily for\u00a02 days in patients with potential Strongyloides exposure is recommended. [37] A responsive patient should experience a 50% reduction within the first 24 hours, whereas an unresponsive patient will exhibit no change in eosinophil count. It is crucial to remain vigilant of potential intracranial hemorrhage, which may persist up to a week after treating hyperleukocytosis. This risk is attributed to reperfusion injury after restoring blood flow.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Severe HES is defined by an absolute eosinophil count of 100 x 10 9 /L (>100,000 cells/\u00b5L) and signs of hyperleukocytosis involving the nervous and pulmonary systems. In cases of severe HES, treatment involves high-dose intravenous prednisone 1 mg/kg/ day or 1 g/day of methylprednisolone. Patients should be tested for Strongyloides serology before initiating treatment if uncertainty exists regarding prior exposure.\u00a0Prophylaxis with\u00a0ivermectin at 200 mcg/kg/daily for\u00a02 days in patients with potential Strongyloides exposure is recommended. [37] A responsive patient should experience a 50% reduction within the first 24 hours, whereas an unresponsive patient will exhibit no change in eosinophil count. It is crucial to remain vigilant of potential intracranial hemorrhage, which may persist up to a week after treating hyperleukocytosis. This risk is attributed to reperfusion injury after restoring blood flow."}
{"id": "article-149474_28", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "In cases of clinically stable HES, when the decision to proceed with treatment is established, the initial approach should be guided by the variant of HES. [38] Systemic glucocorticoids serve as the primary line of therapy for most HES variants. According to a multicenter retrospective analysis of 188 HES patients, 85% achieved partial or complete symptom remission within 1 month, and maintenance therapy was sustained for a minimum of 2 months to a maximum of 20 years. The median maintenance dose of prednisone for remission maintenance was 10 mg daily, with a median maximal dose of 40 mg. [17] Patients displaying resistance to steroids should be re-evaluated and initiated on imatinib. In instances of secondary HES, treatment should be directed\u00a0at addressing the underlying cause.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. In cases of clinically stable HES, when the decision to proceed with treatment is established, the initial approach should be guided by the variant of HES. [38] Systemic glucocorticoids serve as the primary line of therapy for most HES variants. According to a multicenter retrospective analysis of 188 HES patients, 85% achieved partial or complete symptom remission within 1 month, and maintenance therapy was sustained for a minimum of 2 months to a maximum of 20 years. The median maintenance dose of prednisone for remission maintenance was 10 mg daily, with a median maximal dose of 40 mg. [17] Patients displaying resistance to steroids should be re-evaluated and initiated on imatinib. In instances of secondary HES, treatment should be directed\u00a0at addressing the underlying cause."}
{"id": "article-149474_29", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Tyrosine kinase inhibitors, such as imatinib mesylate (IM), have demonstrated notable efficacy in treating F/P pos HES at the recommended daily dosage of 400 mg. The mechanism of action involves the inactivation of downstream phosphorylation by occupying the kinase pocket, which functions as the ATP-binding site in the inactive conformation of genes abl, c-kit, PDGFRA, and PDGFRB. [39] Patients with F/P pos status typically experience a rapid response within a few days, whereas those with F/P neg status observe a response over several weeks.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Tyrosine kinase inhibitors, such as imatinib mesylate (IM), have demonstrated notable efficacy in treating F/P pos HES at the recommended daily dosage of 400 mg. The mechanism of action involves the inactivation of downstream phosphorylation by occupying the kinase pocket, which functions as the ATP-binding site in the inactive conformation of genes abl, c-kit, PDGFRA, and PDGFRB. [39] Patients with F/P pos status typically experience a rapid response within a few days, whereas those with F/P neg status observe a response over several weeks."}
{"id": "article-149474_30", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Hydroxyurea serves as a viable second-line treatment for individuals who are unresponsive to glucocorticoid monotherapy. Its mechanism of action centrally targets eosinophil development, making it less suitable when an acute decrease in eosinophil count is needed. Hydroxyurea can be\u00a0prescribed\u00a0as monotherapy or combination therapy with prednisone. The recommended dose is 0.5 to 2 g daily, contingent on patient tolerance. Studies have shown that a combination therapy approach (2 g hydroxyurea with 1 mg/kg of prednisone daily) results in complete remission for 60% of patients, surpassing the 33% remission rate observed with hydroxyurea monotherapy alone. [40]", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Hydroxyurea serves as a viable second-line treatment for individuals who are unresponsive to glucocorticoid monotherapy. Its mechanism of action centrally targets eosinophil development, making it less suitable when an acute decrease in eosinophil count is needed. Hydroxyurea can be\u00a0prescribed\u00a0as monotherapy or combination therapy with prednisone. The recommended dose is 0.5 to 2 g daily, contingent on patient tolerance. Studies have shown that a combination therapy approach (2 g hydroxyurea with 1 mg/kg of prednisone daily) results in complete remission for 60% of patients, surpassing the 33% remission rate observed with hydroxyurea monotherapy alone. [40]"}
{"id": "article-149474_31", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Interferon-\u03b1 (IFN-\u03b1) is a pleiotropic cytokine that can target eosinophils, inhibit the proliferation of CD4 T cells, and inhibit IL-5 production by CD3-CD4+ T cells in vitro. Prior studies have demonstrated its viability as a treatment option for F/P neg HES, particularly when used with glucocorticoids. However, its extensive side effect profile, encompassing flu-like symptoms, myelosuppression, transaminitis, fatigue, myalgias, depression, and suicidal ideation, has posed a challenge and led to treatment interruptions in multiple cases. [41] [17] [42] IFN-\u03b1 treatment has been well-received by patients with the L-HES variant. At the same time, individuals with other causes may benefit from a hydroxyurea or IFN-\u03b1 trial. [43] [17] The optimal dosage schedule for IFN-\u03b1 remains undefined. However, a suggested starting dose is 1 million units per injection daily, with incremental increases of 0.5 to 1 million units per injection every\u00a02 weeks until the desired effect is reached. Dosages can range from 1 to 4 million units per dose up to\u00a07 times weekly. Pegylated IFN-2\u03b1, exhibiting efficacy and side effect profiles similar to IFN-\u03b1, requires weekly treatment, rendering it a more tolerable option.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Interferon-\u03b1 (IFN-\u03b1) is a pleiotropic cytokine that can target eosinophils, inhibit the proliferation of CD4 T cells, and inhibit IL-5 production by CD3-CD4+ T cells in vitro. Prior studies have demonstrated its viability as a treatment option for F/P neg HES, particularly when used with glucocorticoids. However, its extensive side effect profile, encompassing flu-like symptoms, myelosuppression, transaminitis, fatigue, myalgias, depression, and suicidal ideation, has posed a challenge and led to treatment interruptions in multiple cases. [41] [17] [42] IFN-\u03b1 treatment has been well-received by patients with the L-HES variant. At the same time, individuals with other causes may benefit from a hydroxyurea or IFN-\u03b1 trial. [43] [17] The optimal dosage schedule for IFN-\u03b1 remains undefined. However, a suggested starting dose is 1 million units per injection daily, with incremental increases of 0.5 to 1 million units per injection every\u00a02 weeks until the desired effect is reached. Dosages can range from 1 to 4 million units per dose up to\u00a07 times weekly. Pegylated IFN-2\u03b1, exhibiting efficacy and side effect profiles similar to IFN-\u03b1, requires weekly treatment, rendering it a more tolerable option."}
{"id": "article-149474_32", "title": "Hypereosinophilic Syndrome -- Treatment / Management", "content": "Immunomodulatory agents, such as mepolizumab and benralizumab, a humanized monoclonal antibody against IL-5, have also proven effective in F/P neg HES cases. [44] [45] In a significant randomized control trial assessing its efficacy in patients with F/P neg HES on prednisone monotherapy, results indicated that 84% of patients managed to reduce their prednisone dosage without a subsequent increase in the clinical activity of HES. This underscores mepolizumab as a favorable steroid-sparing option. [46] [47] The indicated dosage entails\u00a03 subcutaneous injections of 100 mg, totaling 300 mg, administered once every\u00a04 weeks.", "contents": "Hypereosinophilic Syndrome -- Treatment / Management. Immunomodulatory agents, such as mepolizumab and benralizumab, a humanized monoclonal antibody against IL-5, have also proven effective in F/P neg HES cases. [44] [45] In a significant randomized control trial assessing its efficacy in patients with F/P neg HES on prednisone monotherapy, results indicated that 84% of patients managed to reduce their prednisone dosage without a subsequent increase in the clinical activity of HES. This underscores mepolizumab as a favorable steroid-sparing option. [46] [47] The indicated dosage entails\u00a03 subcutaneous injections of 100 mg, totaling 300 mg, administered once every\u00a04 weeks."}
{"id": "article-149474_33", "title": "Hypereosinophilic Syndrome -- Differential Diagnosis", "content": "The differential diagnosis of HES varies depending on the extent of eosinophilia. [48]", "contents": "Hypereosinophilic Syndrome -- Differential Diagnosis. The differential diagnosis of HES varies depending on the extent of eosinophilia. [48]"}
{"id": "article-149474_34", "title": "Hypereosinophilic Syndrome -- Differential Diagnosis", "content": "In mild to moderate eosinophilia cases, consideration\u00a0is given to reactive eosinophilia attributed to infectious and parasitic diseases. This possibility requires a meticulous evaluation, a detailed history and examination, and testing for ova, parasites, and helminth infections. It is important to rule out drugs or natural supplements as primary etiologies.", "contents": "Hypereosinophilic Syndrome -- Differential Diagnosis. In mild to moderate eosinophilia cases, consideration\u00a0is given to reactive eosinophilia attributed to infectious and parasitic diseases. This possibility requires a meticulous evaluation, a detailed history and examination, and testing for ova, parasites, and helminth infections. It is important to rule out drugs or natural supplements as primary etiologies."}
{"id": "article-149474_35", "title": "Hypereosinophilic Syndrome -- Differential Diagnosis", "content": "In cases of more moderate to severe manifestations of HES, hematologic and other neoplastic diseases should be considered. Acute eosinophilic leukemia presents an increased number of immature eosinophils in the peripheral blood, bone marrow, or tissues, accompanied by more than 10% blasts in the marrow, distinguishing it from HES. Chronic myeloid leukemia is another diagnosis that may be differentiated from HES as it typically does not cause clinical complications of eosinophilia and can be identified by the detection of BCR:ABL fusion mRNA.", "contents": "Hypereosinophilic Syndrome -- Differential Diagnosis. In cases of more moderate to severe manifestations of HES, hematologic and other neoplastic diseases should be considered. Acute eosinophilic leukemia presents an increased number of immature eosinophils in the peripheral blood, bone marrow, or tissues, accompanied by more than 10% blasts in the marrow, distinguishing it from HES. Chronic myeloid leukemia is another diagnosis that may be differentiated from HES as it typically does not cause clinical complications of eosinophilia and can be identified by the detection of BCR:ABL fusion mRNA."}
{"id": "article-149474_36", "title": "Hypereosinophilic Syndrome -- Differential Diagnosis", "content": "Systemic mastocytosis with eosinophilia is\u00a0a relevant differential diagnosis characterized by its association with D816V mutations in the KIT gene. Notably, systemic mastocytosis with eosinophilia has an equal sex distribution compared to HES, which is more predominant in men. Moreover, the ratio of absolute eosinophil count (AEC) to serum total tryptase (AEC/tryptase) is <100 in systemic mastocytosis with eosinophilia vs >100 in HES. [49] [50]", "contents": "Hypereosinophilic Syndrome -- Differential Diagnosis. Systemic mastocytosis with eosinophilia is\u00a0a relevant differential diagnosis characterized by its association with D816V mutations in the KIT gene. Notably, systemic mastocytosis with eosinophilia has an equal sex distribution compared to HES, which is more predominant in men. Moreover, the ratio of absolute eosinophil count (AEC) to serum total tryptase (AEC/tryptase) is <100 in systemic mastocytosis with eosinophilia vs >100 in HES. [49] [50]"}
{"id": "article-149474_37", "title": "Hypereosinophilic Syndrome -- Differential Diagnosis", "content": "Another crucial differential in the diagnostic workup of HES is eosinophilic granulomatosis with polyangiitis (EGPA). The key distinguishing factor between HES and EGPA is the presence of vasculitis in the latter. [51]", "contents": "Hypereosinophilic Syndrome -- Differential Diagnosis. Another crucial differential in the diagnostic workup of HES is eosinophilic granulomatosis with polyangiitis (EGPA). The key distinguishing factor between HES and EGPA is the presence of vasculitis in the latter. [51]"}
{"id": "article-149474_38", "title": "Hypereosinophilic Syndrome -- Prognosis", "content": "While specific prognostic markers for patients with HES are not well-established, the prognosis varies widely. It spans from mildly symptomatic cases, manageable through observation and follow-up, to severe disease resulting in the development of fatal, end-organ damage such as leukemia or irreversible heart failure.", "contents": "Hypereosinophilic Syndrome -- Prognosis. While specific prognostic markers for patients with HES are not well-established, the prognosis varies widely. It spans from mildly symptomatic cases, manageable through observation and follow-up, to severe disease resulting in the development of fatal, end-organ damage such as leukemia or irreversible heart failure."}
{"id": "article-149474_39", "title": "Hypereosinophilic Syndrome -- Prognosis", "content": "In recent years, the prognosis of HES has improved, secondary to advancements in the earlier detection of complications, enhanced surgical management of cardiac involvement, and a broader array of therapeutic modalities targeting the underlying cause of HES. Further studies regarding the pathophysiology of different disease variants hold promise for refining therapeutic strategies and enhancing a favorable prognosis. [4]", "contents": "Hypereosinophilic Syndrome -- Prognosis. In recent years, the prognosis of HES has improved, secondary to advancements in the earlier detection of complications, enhanced surgical management of cardiac involvement, and a broader array of therapeutic modalities targeting the underlying cause of HES. Further studies regarding the pathophysiology of different disease variants hold promise for refining therapeutic strategies and enhancing a favorable prognosis. [4]"}
{"id": "article-149474_40", "title": "Hypereosinophilic Syndrome -- Complications", "content": "Complications of HES are attributed to the type and degree of end-organ involvement. The most fatal complications are leukemias, irreversible heart failure, endocarditis, and severe restrictive cardiomyopathy, causing ventricular arrhythmia due to alterations in the cardiac conducting system.", "contents": "Hypereosinophilic Syndrome -- Complications. Complications of HES are attributed to the type and degree of end-organ involvement. The most fatal complications are leukemias, irreversible heart failure, endocarditis, and severe restrictive cardiomyopathy, causing ventricular arrhythmia due to alterations in the cardiac conducting system."}
{"id": "article-149474_41", "title": "Hypereosinophilic Syndrome -- Deterrence and Patient Education", "content": "Patients should seek medical attention if they have multiple unexplained symptoms such as dyspnea, chest pain, cough, fevers, chills, palpitations, gastritis, or other dermatologic symptoms such as eczema or dermatitis. Patients should provide physicians with detailed history, including past medical history, travel and social history, medications, and over-the-counter supplements.", "contents": "Hypereosinophilic Syndrome -- Deterrence and Patient Education. Patients should seek medical attention if they have multiple unexplained symptoms such as dyspnea, chest pain, cough, fevers, chills, palpitations, gastritis, or other dermatologic symptoms such as eczema or dermatitis. Patients should provide physicians with detailed history, including past medical history, travel and social history, medications, and over-the-counter supplements."}
{"id": "article-149474_42", "title": "Hypereosinophilic Syndrome -- Enhancing Healthcare Team Outcomes", "content": "HES is a multisystemic condition that necessitates a comprehensive,\u00a0interprofessional approach. Consultation with sub-specialists should be pursued as necessary, contingent upon end-organ involvement. Active communication among specialists from diverse fields could lead to early detection of HES, identifying the most suitable treatment strategy, and enhancing quality of life.", "contents": "Hypereosinophilic Syndrome -- Enhancing Healthcare Team Outcomes. HES is a multisystemic condition that necessitates a comprehensive,\u00a0interprofessional approach. Consultation with sub-specialists should be pursued as necessary, contingent upon end-organ involvement. Active communication among specialists from diverse fields could lead to early detection of HES, identifying the most suitable treatment strategy, and enhancing quality of life."}
{"id": "article-149474_43", "title": "Hypereosinophilic Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Hypereosinophilic Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}